Galapagos N.V.
GLPG.BR
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.11B
Close$
Share Statistics
| Market cap | $2.11 Billion |
|---|---|
| Enterprise Value | $2.05 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.12 |
| Beta | 0 |
| Outstanding Shares | 65,838,197 |
Return
| Return on Equity | 18.34% |
|---|---|
| Return on Assets | 17.69% |
| Return on Invested Capital | 18.04% |
Valuation & Multiples
| P/E Ratio | 3.56 |
|---|---|
| PEG | -3.49 |
| Price to Sales | 1.07 |
| Price to Book Ratio | 0.33 |
| Enterprise Value to Revenue | 2.07 |
| Enterprise Value to EBIT | 3.47 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Galapagos NV
452 employees
CEO: Onno van de Stolpe Galapagos N.V. is a fully-integrated biopharmaceutical firm dedicated to discovering, developing, and bringing to market innovative therapies for conditions where patient needs are largely unaddressed. The company boasts a robust pipelin...